Expression of Basic Fibroblast Growth Factor in Primary Human Renal Tumors: Correlation With Poor Survival

Nanus, David M.; Schmitz‐Dräger, Bernd J.; Motzer, Robert J.; Lee, Anita C.; Vlamis, Vaia; Cordon‐Cardo, Carlos; Albino, Anthony P.; Reuter, Victor E.

doi:10.1093/jnci/85.19.1597

Cited by 111 publications

(50 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We also examined the expression of several angiogenesis-related genes in primary and metastasis tumors, including bFGF, [13][14][15][16][17] VEGF, [17][18][19][20][21] and IL-8, 22 as the expression of these genes has been found previously to be significant prognostic factors of metastasis in patients with RCC. However, we were not able to verify these observations with regard to the metachronous metastasis of CRCC.…”

Section: Discussionmentioning

confidence: 99%

Levels of angiogenesis and expression of angiogenesis‐related genes are prognostic for organ‐specific metastasis of renal cell carcinoma

Fukata

Inoue

Kamada

et al. 2005

Cancer

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Levels of angiogenesis and expression of angiogenesis‐related genes are prognostic for organ‐specific metastasis of renal cell carcinoma

Fukata

Inoue

Kamada

et al. 2005

Cancer

View full text Add to dashboard Cite

show abstract

“…One of these, basic fibroblast growth factor (bFGF), is a heparin-binding protein that has been implicated in the growth and metastases of a variety of solid cancers (Nanus et al, 1993;Zimering et al, 1993).…”

mentioning

confidence: 99%

Low levels of basic fibroblast growth factor (bFGF) are associated with a poor prognosis in human breast carcinoma

Colomer

Aparicio²,

Montero³

et al. 1997

Br J Cancer

View full text Add to dashboard Cite

Summary It has been suggested that angiogenesis and angiogenic factors may be strong predictors of relapse in patients with breast carcinoma. We measured the levels of the angiogenic peptide basic fibroblast growth factor (bFGF) in 140 breast tumour cytosols using an immunoassay. There were no significant differences in bFGF levels between breast non-malignant lesions and primary carcinomas. In 124 cases with primary breast cancer, we observed an association of low bFGF levels (< 400 pg mg-') with increasing tumour size (P = 0.023) and stage of disease (P= 0.002). bFGF levels did not correlate with other variables, including axillary nodes, hormone receptors, cathepsin D and the serum tumour markers CA15.3 and CEA. With a median follow-up of 44.0 months, breast cancer patients with low levels of bFGF had a significantly shorter disease-free survival (DFS) than patients with elevated bFGF (log-rank, P < 0.0001). In a multivariate analysis of DFS, only bFGF, T-stage and histological grade showed statistical significance. In a parallel evaluation of circulating bFGF, we did not observe a correlation between the serum and tissue bFGF levels in the 29 selected cases with matched determinations. Our results indicate that low bFGF levels in breast carcinoma are an independent prognostic indicator of poor prognosis and disease recurrence.

show abstract

“…Immunohistochemical studies have shown that immunoreactivity against FGF-2 is found in both the blood vessel wall and the extracellular matrix in most RCCs, but cytoplasmic FGF-2 is present in only 16% of the tumors. 29) We have also failed to detect overexpression of FGF-2 gene in RCC tissues and to find any difference in the serum FGF-2 protein levels between Fig. 3.…”

Section: Discussionmentioning

confidence: 64%

Increased Serum Levels of Vascular Endothelial Growth Factor in Patients with Renal Cell Carcinoma

Sato

Tsuchiya

Sasaki

et al. 1999

Japanese Journal of Cancer Research

View full text Add to dashboard Cite

Neovascularization, an essential event for the growth of solid tumors, is regulated by a number of angiogenic factors. One such factor, vascular endothelial growth factor (VEGF), is considered to exert a potent angiogenic activity, as indicated by immunohistochemical and molecular evidence. In this study we investigated the serum VEGF level (s-VEGF) in patients with renal cell carcinoma (RCC). s-VEGF in peripheral blood samples was analyzed in 40 RCC patients and 40 patients without cancer (controls) using a sandwich enzyme-linked immunoassay. In 20 RCC patients, serum samples were obtained separately from the bilateral renal veins. s-VEGF was also measured before, 4 and 8 weeks after nephrectomy in 11 patients. There were significant differences in s-VEGF between the RCC patients and the controls (207.3 ± ± ± ±32.9 vs. 71.5 ± ± ± ±9.1 pg/ml, mean± ± ± ±SE) (P < < < <0.005), between the tumor-bearing renal veins and the contralateral ones (P < < < <0.01), between the pre-and post-nephrectomy situations (P < < < <0.01) and among the various parameters of tumor status such as tumor extent (P < < < <0.001) and existence of metastasis (P < < < <0.001). s-VEGF significantly correlated with the tumor volume obtained by a three-dimensional measurement (r = = = =0.802, P < < < <0.0001).The sensitivity and specificity of s-VEGF at the cut-off level of 100 pg/ml, as determined by the receiver-operating-characteristics curve, were 80.0% and 72.5%, respectively. The results indicate that tumor tissue of RCC liberates VEGF into the systemic blood flow and that s-VEGF is a possible marker for RCC.

show abstract

Expression of Basic Fibroblast Growth Factor in Primary Human Renal Tumors: Correlation With Poor Survival

Cited by 111 publications

References 0 publications

Levels of angiogenesis and expression of angiogenesis‐related genes are prognostic for organ‐specific metastasis of renal cell carcinoma

Levels of angiogenesis and expression of angiogenesis‐related genes are prognostic for organ‐specific metastasis of renal cell carcinoma

Low levels of basic fibroblast growth factor (bFGF) are associated with a poor prognosis in human breast carcinoma

Increased Serum Levels of Vascular Endothelial Growth Factor in Patients with Renal Cell Carcinoma

Contact Info

Product

Resources

About